Will try to summarize my thoughts so this isn't too long.
http://investorshub....x?board_id=4924
ABOUT NANOLOGIX:
NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.
The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.
The BNP™ ultra-fast test kit sets a new standard for accurate, high-speed diagnostics. With results two to four times faster than traditional Petri dish methods, NanoLogix technology represents a revolutionary next step in disease identification.
Uses for NanoLogix’s very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.
NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
[media]http://www.youtube.com/watch?v=oMoX5dDFOiE&feature=player_embedded[/media]
https://www.nanologi...m/products.html
Nanologix story:
*March 2007 stock price $.13
*Change of CEO March 2007, leading to change in focus for company from filing patents, increased dilution rates, hype-marketing on hydrogen, etc. to Rapid Diagnostics: BNC-BNP
*March 2009 stock price bases at $.05-.06
*Nov 2009, share price climbs to 60 cents, then declines to base below 50 cents.
*Worked +1 year with EPA - now have signed CRADA for joint development. Based on discussion with EPA, NNLX invented and filed for Patent on BNF.
*Based on BNF-BNP; new hire at BioStart Lab invented and filed Quick Test Kits
*April 2010; NNLX builds Clean Room, builds expectations, pump from others, etc. and price climbs on huge volume to high of $1.48, then three spikes over $1 from Nov 09 to July 2010.
*Dec 2010 price trends down to current at 40 to 50 cent range, roughly where it was Dec 2009 thru May 2010.
*Capitulation Dec 10, 2010 was on volume of 630k shares, low of 33 cents, rather similar to Dec 15-15, 2009 when stock was trading at 53 cents, low of 35 cents on volume of roughly 600k.
*Dec 2010: Company has patents and potential, but no FDA-AOAC Approval. Company has lots of irons in the fire, but does not yet appear to have huge sales.
Going forward what is LIKELY to happen?
Non-Believers think the technology does not work, all will be for nothing and this is just another typical pink sheet stock. Anyone that talks negative is a 'basher' and anyone positive a 'pumper'. Why is there no middle ground for rational investment discussion?
Believers - investors think "It's the TECHNOLOGY stupid" and the company will succeed. Company has issued roughly 104 million shares, 200 million authorized so not against the wall yet. Company has CRADA with EPA, testing with TMC and Battelle, new products-patents-management, no debt, company management appear aligned with shareholders, as evidenced by Shareholders Rights Plan and current management preventing company assets to be spun off under former management.
IF the TMC work leads to success, then they document and publish papers - file and obtain FDA-AOAC approval to use device, which then could lead to sales-revenue-profits, but this is months away. This would open the door to direct sales to all hospitals in the USA for medical sales.
IF the EPA work is successful, then NNLX sellss kits to the EPA across the USA.
IF the Battelle work is successful, then NNLX sells kits for bioterrorism testing - choleria, etc.
IF above is successful, then someone tests for e-coli and sam-and-ella, and NNLX sells kits to the food & beverage industry.
We used analogy's in drill oil wells as still can't simply look at the ground and predict what would happen if we drill. But by evaluating the well across the fence, we could get a very good idea what might happen. If we had wells east and west of our project to evaluate, one gets an even better idea! Make sense?
Feel free to revise and adjust dates - details above as this is only a rough outline for discussion.
DNDN: Dendreon Corp. - Biotechnology company in Healthcare Sector.
http://finance.yahoo...m/q?s=dndn&ql=1
Without going thru entire history of company:
*Share price April 2005 thru Feb 2007 ranged from $3.68 to $7.37
*Spike up on EXPECTATIONS, higher volume, Share price peaked at $25.25 on 4-13-07.
*Expectations not met, share price declined June 2007 t0 2-20-09, low of $3.26. Notice this low is just below low of Feb 2007!
Capitulation: 2-27-09 thru 3-13-09; low price of $2.55 on higher volume.
*Ramp price back to base 3-20 to 2-27-09; Price $3.82 to $4.52
*DNDN price jumps to $22.10 and trends UP. Company announced that its main drug, Provenge, prolonged the lives of men with advanced prostate cancer in a phase 3 FDA study. Dendreon hopes for regulatory approval soon so it can get the drug to market in 2010.
*52 week high price 4-30-2010 at $57.67 when FDA approves companys Provenge, the first vaccine for any cancer, to treat advanced prostate cancer.
*Revenue: 4th Qtr 2009: $21k, 1st Qtr 2010 $21k, 2nd Qtr 2010 $2.8m, 3rd Qtr 2010 $20 m
*Share price Dec 10, 2010 $37.65
The reason personally believe it's an analogy as both are BioTech companies, working to bring their first product to market. Nanologix has been trying, but does not appear to be able to generate significant sales without FDA or AOAC approval. Therefore they now appear to be working with world-class and respected organizations in each field of bio-terrorism, medical, and environmental industries.
What happens next? If the TMC testing for GBS goes as it has since Sept 2009, then it will be successful, and they will likely make another announcement similar to what TMC independently released. Per the jump in DNDN share price, believe NNLX will experience a similar event.
With TMC success with GBS, we should get news of a follow up as they previously mentioned MRSA.
The Battelle testing am personally expecting to take longer, and should open the door to increased sells for bio-terrorism.
Am waiting for more news as CEO previously announced they were also targeting food and beverage industry.
Per DNDN, the share price advanced BEFORE the revenues were announced. Therefore for those seeking Sales and Revenue numbers, this is a historical measure and the price jumped up months before earnings were released. So waiting for release of financial numbers would be a great way to miss the opportunity.
DNDN has 144.3 million shares Outstanding, and Nanologix has an estimated 105 to 110 million. Those saying there are too many shares to be successful; why has DNDN been successful with more shares?
Related 'market cap too high!' concerns? DNDN now has a market cap of $5.4 billion on last quarter revenue of 20.2 million, Net Profit of -$79.3 million dollars. Therefore the company is still operating at a loss, but is valued over $5 billion. Humm. Rather difficult to calculate a PE with negative earnings... But some see value!
Bottom line, News of the Clinical trial SHOULD give the share price a huge upward boost, and final FDA/AOAC/Battelle/EPA approvals more support. Earnings trail news and share price! Have found at least one company with huge gains in share price, in same industry, with more shares outstanding and still no net earnings after several years.
Looking at Dendreon gives me a rational way to build my personal expectations for what has happened in the past to a similar company, and what could happen to Nanologix if the trial-testing work is successful. Therefore am basing my decisions on these facts, rather than blindly guessing or listening too much to others on message boards. Remember that EVERYONE posting on the message boards has an agenda, whether they are honest about it or not!
anyone care to comment?
NNLX.PK NANOLOGIX INC - Biotechnologies
Linear Mode
